Collaboration on MEDI-488 anti-HIV monoclonal antibody will continue following a review that began in January of the available data ("The Pink Sheet" Jan. 11, T&G-8), Gaithersburg, Md.-based MedImmune reports March 4. The companies have modified their autumn 1991 three-year deal: Merck will fund internal development of MEDI-488 but defer MedImmune research on other anti-HIV MAbs at least until after Phase I trials of MEDI-488.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth